Literature DB >> 15188493

Reversal of multidrug resistance in drug-resistant human gastric cancer cell line SGC7901/VCR by antiprogestin drug mifepristone.

Da-Qiang Li1, Zhi-Biao Wang, Jin Bai, Jie Zhao, Yuan Wang, Kai Hu, Yong-Hong Du.   

Abstract

AIM: To explore the reversal effect of mifepristone on multidrug resistance (MDR) in drug-resistant human gastric cancer cell line SGC7901/VCR and its mechanisms.
METHODS: Expression of multidrug resistance-associated protein(MRP) was detected using reverse transcription-polymerase chain reaction(RT-PCR). Flow cytometry was used to assay the expression of P-glycoprotein(P-gp), Bcl-2, Bax, and the mean fluorescent intensity of intracellular rhodamine 123 in the cells. Meanwhile, the protein levels of Bcl-2 and Bax were also detected by Western blotting analysis. The sensitivity of cells to the anticancer agent, vincrimycin(VCR), and the intracellular [(3) H]VCR accumulation were determined by tetrazolium blue (MTT) assay and a liquid scintillation counter, respectively.
RESULTS: Expression of MRP and P-gp in SGC7901/VCR cells was 6.04-and 8.37-fold higher as compared with its parental SGC7901 cells, respectively. After treatment with 1, 5, 10, and 20 micromol/L mifepristone, SGC7901/VCR cells showed a 1.34-, 2.29-, 3.11-, and 3.71-fold increase in the accumulation of intracellular VCR, a known substrate of MRP, and a 1.03-, 2.04-, 3.08-, and 3.68-fold increase in the retention of rhodamine 123, an indicator of P-gp function, respectively. MTT assay revealed that the resistance of SGC7901/VCR cells to VCR was 11.96-fold higher than that of its parental cells. The chemosensitivity of SGC7901/VCR cells to VCR was enhanced by 1.02-, 7.19-, 12.84-, and 21.17-fold after treatment with mifepristone at above-mentioned dose. After 96 h of incubation with mifepristone 10 micromol/L, a concentration close to plasma concentrations achievable in human, the expression of Bcl-2 protein was decreased to (9.21+/-0.65)% from (25.32+/-1.44)%, whereas the expression of Bax protein was increased to (19.69+/-1.13)% from (1.24+/-0.78)% (P<0.01). Additionally, the effects of mifepristone on the expression of Bcl-2 and Bax proteins in SGC7901/VCR cells were further demonstrated by Western blotting analysis.
CONCLUSION: Mifepristone has potent reversal effect on MDR in SGC7901/VCR via inhibiting the function of MRP and P-gp, modulating the expression of Bcl-2 and Bax proteins, and enhancing the sensitivity to anticancer agent VCR.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15188493      PMCID: PMC4572256          DOI: 10.3748/wjg.v10.i12.1722

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  28 in total

1.  Phase II study of mifepristone (RU486) in refractory ovarian cancer.

Authors:  T F Rocereto; H M Saul; J A Aikins; J Paulson
Journal:  Gynecol Oncol       Date:  2000-06       Impact factor: 5.482

2.  Principles of surgical treatment for curable gastric cancer.

Authors:  Mitsuru Sasako
Journal:  J Clin Oncol       Date:  2003-12-01       Impact factor: 44.544

3.  Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells.

Authors:  S M Hyder; C Chiappetta; G M Stancel
Journal:  Int J Cancer       Date:  2001-05-15       Impact factor: 7.396

4.  RU486 increases radiosensitivity and restores apoptosis through modulation of HPV E6/E7 in dexamethasone-treated cervical carcinoma cells.

Authors:  M C Kamradt; N Mohideen; A T Vaughan
Journal:  Gynecol Oncol       Date:  2000-04       Impact factor: 5.482

5.  Expression of multidrug resistance-related markers in gastric cancer.

Authors:  K Fan; D Fan; L F Cheng; C Li
Journal:  Anticancer Res       Date:  2000 Nov-Dec       Impact factor: 2.480

6.  Reversal of MRP-mediated multidrug resistance in human lung cancer cells by the antiprogestatin drug RU486.

Authors:  L Payen; L Delugin; A Courtois; Y Trinquart; A Guillouzo; O Fardel
Journal:  Biochem Biophys Res Commun       Date:  1999-05-19       Impact factor: 3.575

7.  Introduction of gadd153 gene into gastric cancer cells can modulate sensitivity to anticancer agents in association with apoptosis.

Authors:  R Kim; Y Ohi; H Inoue; K Aogi; T Toge
Journal:  Anticancer Res       Date:  1999 May-Jun       Impact factor: 2.480

8.  Synergistic effects of danazol and mifepristone on the cytotoxicity of UCN-01 in hormone-responsive breast cancer cells.

Authors:  Y Yokoyama; A Shinohara; Y Takahashi; X Wan; S Takahashi; K Niwa; T Tamaya
Journal:  Anticancer Res       Date:  2000 Sep-Oct       Impact factor: 2.480

9.  Transport of phosphatidylserine via MDR1 (multidrug resistance 1)P-glycoprotein in a human gastric carcinoma cell line.

Authors:  Antje Pohl; Hermann Lage; Peter Müller; Thomas Pomorski; Andreas Herrmann
Journal:  Biochem J       Date:  2002-07-01       Impact factor: 3.857

10.  Berberine modulates expression of mdr1 gene product and the responses of digestive track cancer cells to Paclitaxel.

Authors:  H L Lin; T Y Liu; C W Wu; C W Chi
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

View more
  5 in total

1.  Reversal of multidrug resistance in vincristine-resistant human gastric cancer cell line SGC7901/VCR by LY980503.

Authors:  Da-Long Wu; Ying Xu; Li-Xin Yin; Huan-Zhang Lu
Journal:  World J Gastroenterol       Date:  2007-04-21       Impact factor: 5.742

Review 2.  Pregnane X Receptor and P-glycoprotein: a connexion for Alzheimer's disease management.

Authors:  Sumit Jain; Vijay Rathod; Rameshwar Prajapati; Prajwal P Nandekar; Abhay T Sangamwar
Journal:  Mol Divers       Date:  2014-09-12       Impact factor: 2.943

Review 3.  The Role of Mifepristone in Meningiomas Management: A Systematic Review of the Literature.

Authors:  Giulia Cossu; Marc Levivier; Roy Thomas Daniel; Mahmoud Messerer
Journal:  Biomed Res Int       Date:  2015-06-03       Impact factor: 3.411

4.  lncRNA ROR Promotes Gastric Cancer Drug Resistance.

Authors:  Shuai Wang; Wujun Chen; Hualong Yu; Zhengming Song; Qian Li; Xin Shen; Yudong Wu; Lei Zhu; Qingxia Ma; Dongming Xing
Journal:  Cancer Control       Date:  2020 Jan-Dec       Impact factor: 3.302

5.  Mifepristone as a Potential Therapy to Reduce Angiogenesis and P-Glycoprotein Associated With Glioblastoma Resistance to Temozolomide.

Authors:  Monserrat Llaguno-Munive; Sebastián León-Zetina; Inés Vazquez-Lopez; María Del Pilar Ramos-Godinez; Luis A Medina; Patricia Garcia-Lopez
Journal:  Front Oncol       Date:  2020-10-05       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.